Brain radiotherapy added to first-line immunochemotherapy improves survival in patients with treatment-naïve, driver-negative lung adenocarcinoma and synchronous brain metastases.

<1%) showed a trend towards being a favorable factor for PFS (HR = 0.843, P = 0.096). 3.5 Subgroup analysis A subgroup analysis was performed to explore the consistency of the OS benefit derived from combination therapy across various patient characteristics ( Figure 4 ).

also in 53,322 other papers